Moxley et al. evaluated the association of ERCC1 and the response to platinum-based chemotherapy in ovarian cancer and found that negative ERCC1 expression was associated with a better response to platinum-based chemotherapy [10]. Here, ERCC1 is linked to ovarian carcinoma.